Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

VMAT Concurrent Cisplatin Plus Nab-paclitaxel for Local Advanced Cervical Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04017377
Recruitment Status : Not yet recruiting
First Posted : July 12, 2019
Last Update Posted : July 12, 2019
Sponsor:
Information provided by (Responsible Party):
Junjie Wang, Peking University Third Hospital

Brief Summary:
This is a single arm, open-lable Phase I clinical trial. Eligible patients will have Histologically proven stage IB2-IVA cervical cancer. We hypothesize that Nab-paclitaxel in combination with cisplatin and radiotherapy may have anti-tumor activity in patients with cervical cancer. Nab-paclitaxel has not previously been combined with conventional RT-CT to treat cervical cancer.

Condition or disease Intervention/treatment Phase
Cervical Cancer Drug: Drug: Cisplatin; nab-paclitaxel Not Applicable

Detailed Description:
During the phase I study, patients will receive radiation therapy to pelvis (50.4 Gy in 28fractions), and followed by HDR intracavitary (30Gy in 5 fractions) brachytherapy. Concurrent chemotherapy was administered with weekly cisplatin (40 mg/m^2) and an escalating dose of weekly Nab-paclitaxel starting at 10 mg/m^2 up to 70 mg/m^2. Chemotherapy agents were administered in escalating doses to cohorts of three patients at each dose level.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 15 participants
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Study of Radiation Therapy With Concomitant Nab-paclitaxel and Cisplatin Chemotherapy in Patients With Locally Advanced Cervical Cancer
Estimated Study Start Date : July 15, 2019
Estimated Primary Completion Date : June 15, 2020
Estimated Study Completion Date : July 15, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cervical Cancer

Arm Intervention/treatment
Experimental: Chemotherapy+ Radiation therapy

Chemotherapy: Patients firstly receive an escalating dose of weekly Nab-paclitaxel starting at 10 mg/m^2 up to 70 mg/m^2, Patients secondly receive weekly cisplatin (40 mg/m^2). Treatment repeats every week until the disease recurrence or unacceptable toxicity, death or begin a novel therapeutic. Concurrent chemotherapy is a weekly regimen during radiotherapy. Patients will complete at least 4 cycles of concurrent chemoradiotherapy, until the maximal tolerated dose (MTD) appeared.

Radiation therapy: Patients also receive pelvic radiation therapy once daily (Monday-Friday) for a total of 28 fractions and intracavitary brachytherapy twice a week for a total 5 fractions. Complete radiotherapy within 55 days.

Drug: Drug: Cisplatin; nab-paclitaxel
Drug: Paclitaxel for Injection(Albumin Bound). Other Name: Ke ai li, ZhusheyongZishanchun(Baidanbai Jiehexing)




Primary Outcome Measures :
  1. Maximum Tolerated Dose(MTD)/Recommended Dose(RD) [ Time Frame: Up to 5 weeks ]
    Maximum Tolerated Dose (MTD) will be defined during the Dose Escalation Stage based on evaluation of the number of patients with Dose-limiting Toxicity (DLT). The MTD will be used to determine the Recommended Dose (RD).


Secondary Outcome Measures :
  1. Number of patients with Dose Limiting Toxicity (DLT) [ Time Frame: Up to 5 weeks ]
    Dose-limiting toxicity is defined as an adverse event that is considered to be drug-related and meets one of the Protocol definitions.

  2. Objective response rate (ORR) [ Time Frame: Up to 5 weeks ]
    ORR was assessed by the site Investigator using RECIST 1.1 and was defined as the percentage of patients with a confirmed overall response of CR or PR.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age ≥ 18 years and ≤ 75 years.
  • Patients with histologically confirmed newly diagnosed advanced cervical cancer (squamous cell carcinoma, adenocarcinoma, and adenosquamous cell carcinoma): Federation of Gynecology and Obstetrics (FIGO) clinical stages IB2-IVA.
  • At least one measurable objective lesion was identified based on the RECIST1.1 criteria;
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-2;
  • The expected survival after surgery ≥ 3 months;
  • LVEF≥55%;
  • Bone marrow function: Neutrophils ≥ 1.5×10^9/L, platelets ≥ 100×10^9/L, and hemoglobin ≥ 90 g/L;
  • Liver and renal function: Serum creatinine ≤ 1.5 times the upper limit of normal. AST and ALT ≤ 2.5 times the upper limit of normal Total bilirubin ≤ 1.5 times the upper limit of normal, or ≤ 2.5 times the upper limit of normal in patients with Gilbert's syndrome.
  • Subjects of child-bearing age must agree to take effective contraceptive measures during the study period; Serum or urine pregnancy tests must be negative for women of childbearing age;
  • Women must not lactate;
  • Signed informed content obtained prior to treatment;

Exclusion Criteria:

  • Patients previously treated with nab-paclitaxel;
  • Patients previously undergoing abdominal or pelvic radiotherapy;
  • Patients with CNS diseases or brain metastases;
  • Other malignant tumors other than cervical cancer occurred in the past 5 years;
  • Patients who had Grade 2 or above Peripheral neuropathy;
  • Patients had uncontrolled serious medical condition that the investigator considered may affect the subject's to receive treatment under the study program, For example, patients with severe medical diseases, including severe heart disease, cerebrovascular disease, uncontrolled diabetes, uncontrolled hypertension, uncontrolled infection, active peptic ulcer, etc;
  • Dementia, changing of mental state or any mental illness which could hinder understanding or informed consent or fill out questionnaires;
  • History of allergy or hypersensitivity to any therapeutic ingredient;
  • Combined with other malignant tumors excepted pancreatic cancer within the first 5 years of randomization, excepted well-treated basal cell or squamous cell carcinoma of the skin, localized prostate cancer after radical resection, and ductal carcinoma in situ of the breast after radical resection;
  • Previously received systemic therapy for advanced/metastatic pancreatic cancer;
  • Subjects who had previously been pathologically diagnosed with squamous cell carcinoma (no organ limitation) and received neoadjuvant/adjuvant therapy with taxa regimen;
  • Patients who had Grade 2 or above Peripheral neuropathy;
  • Known to be allergic, highly sensitive or intolerant to the study-related drugs or their excipients;
  • Participation in any trial drug treatment or another interventional clinical trial 30 days before screening period;
  • Severe infections including, but not limited to, complications of infection, bacteremia or severe pneumonia that require hospitalization within 4 weeks of study treatment initiation;
  • Subjects had hepatitis b surface antigen (HBsAg)-positive and HBV- DNA titer in peripheral blood greater than or equal to 1000 copy number /L; If HBsAg is positive and the peripheral blood HBV-DNA <1000 copy number /L, the subjects will be eligible for inclusion if the investigator considers that chronic hepatitis b is stable and does not increase the risk of subjects;
  • Human immunodeficiency virus (HIV)- or hepatitis C virus (HCV) positive patients;
  • The researchers considered that there were other conditions that were not suitable for enrollment.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04017377


Contacts
Layout table for location contacts
Contact: Junjie Wang, MD, PhD 13701076310 junjiewang_edu@sina.cn
Contact: Ping Jiang, MD 13439796018 jp7962@sohu.com

Sponsors and Collaborators
Peking University Third Hospital
Investigators
Layout table for investigator information
Principal Investigator: Junjie Wang, MD, PhD Peking University Third Hospital

Layout table for additonal information
Responsible Party: Junjie Wang, Principal Investigator, Peking University Third Hospital
ClinicalTrials.gov Identifier: NCT04017377     History of Changes
Other Study ID Numbers: M2019163
First Posted: July 12, 2019    Key Record Dates
Last Update Posted: July 12, 2019
Last Verified: July 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Uterine Cervical Neoplasms
Uterine Neoplasms
Genital Neoplasms, Female
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Uterine Cervical Diseases
Uterine Diseases
Genital Diseases, Female
Paclitaxel
Albumin-Bound Paclitaxel
Cisplatin
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action